Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if a combination of nivolumab and
ipilimumab can help to control locally advanced or metastatic (has spread) renal medullary
carcinoma (RMC).
This is an investigational study. Nivolumab is FDA approved and commercially available to
treat many types of cancer, including renal cell cancer after patients have received therapy
to control blood vessel growth. Ipilimumab is FDA approved and commercially available to
treat metastatic melanoma. It is considered investigational to use nivolumab and ipilimumab
to treat RMC.
The study doctor can explain how the study drugs are designed to work.
Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.